Chronic Granulomatous Disease (CGD) is a rare genetic disorder that affects the immune system, specifically the ability of phagocytes to produce reactive oxygen species (ROS) necessary for ...

Prime Medicine, Inc. faces risks in the gene editing sector despite positive developments, caution advised for retail investors. Click for my PRME stock update.

“Based on data from our preclinical studies, we believe PM359 has the potential to sufficiently correct a prevalent disease-causing mutation of CGD, leading to amelioration of disease for these ...

Prime Medicine has been granted approval by the US Food and Drug Association (FDA) to initiate trials of the first-ever prime editing drug. The FDA cleared Prime Medicine’s investigational new ...